Urology Times staff

The ExoDx Prostate test helps physicians determine whether a prostate biopsy is necessary when PSA screening is ambiguous.

In terms of physician burnout, “The pandemic has only made a bad situation worse,” says Raj S. Pruthi, MD, MHA, FACS.

Frontline immune checkpoint inhibitor therapy may improve overall survival in this setting.

Around the Practice: Metastatic Castrate Resistant Prostate Cancer

Around the Practice: High-Risk Renal Cell Carcinoma

Hamilton discusses findings from a recent study published in European Urology.

Loeb and Stork offer pointers for beginners and current users alike.

“I think one of the issues that we face as physicians…is during training, long hours and a lack of control over our schedule indoctrinates surgeons with habits that may be counterproductive to achieving life balance after entering practice,” says Raj S. Pruthi, MD, MHA FACS.

Galsky highlights final OS data from the IMvigor130 trial, along with an exploratory analysis examining outcomes by type of chemotherapy used.

Both medical professionals bring experience and expertise that will elevate the future work of the publication.

Jason Zhu, MD, discusses factors he considers when choosing treatment for patients with lymph node–positive prostate cancer after prostatectomy.

Attorneys Acacia Brush Perko, Esq, and Kenton H. Steele, Esq, provide an overview of malpractice claims.

The study encompassed the prostatic urethral lift (UroLift), water vapor thermal therapy (Rezum), and temporary implantable nitinol device (iTIND).

Ward's analysis includes a discussion of adjuvant radiotherapy versus early salvage radiotherapy.

“This paper shows that our efforts to reduce… opioid exposure in the postoperative setting is reducing new persistent opioid use,” says Matthew S. Lee, MD.

Michael Devitt, MD, discusses the choice between erdafitinib and enfortumab vedotin in previously treated urothelial carcinoma.

“This test requires just one millimeter of cancer on a biopsy on five consecutive slides,” says Eric A. Klein, MD.

Dr. Ronald S. Swerdloff says Jatenzo showed “no evidence of liver toxicity.”

Tagawa draws specific attention to the targeted radioligand therapy 177Lu-PSMA-617.

The PARP inhibitors olaparib and rucaparib are approved by the FDA for the treatment of patients with metastatic castration-resistant prostate cancer.

Robert Dreicer, MD, discusses emerging strategies for overcoming resistance to second-generation antiandrogens in prostate cancer.

“We found that a remarkable percentage of patients were getting narcotics refills from non urologists,” said Jay Simhan, MD, FACS.

Leonard G. Gomella, MD, discusses questions that still need to be resolved with biomarkers for the diagnosis and management of patients with prostate cancer.

“Because so many disease processes that we deal with are related to tobacco use and smoking specifically… I think this is absolutely our domain,” says Richard S. Matulewicz, MD, of tobacco cessation counseling and treatment.

Dr. Primo Lara, Jr., executive associate dean for Cancer Programs, School of Medicine, at UC Davis Comprehensive Cancer Center, highlights the need for personalized medicine using multidisciplinary care for patients with renal cell carcinoma.

Scott T. Tagawa, MD, highlights pivotal research and next steps with the alpha particle–emitting radioactive therapeutic agent radium-223 in prostate cancer.

“As we suspected, the more work interfered with their freedom to use the restroom, the fewer times they urinated during the work day,” says W. Stuart Reynolds, MD, MPH, FACS.

Jatenzo is approved by the FDA as a testosterone replacement therapy for men with certain forms of hypogonadism.

Dr. Leonard G. Gomella discusses emerging biomarkers and the use of MRI for the early detection of prostate cancer.

Michael E. Hurwitz, MD, PhD, discusses how immune checkpoint inhibitors have transformed the first-line setting in advanced renal cell carcinoma.